EUVIMEDEUVIMED entdecken
Open Access

Autoantibodies against type I interferons correlate with low CD169/SIGLEC1 and severe non-viral infections in ER patients

Olga Staudacher iD, Tim Meyer iD, Bengisu Akbil iD, Miriam Mayer iD, Carolin Schmoll, Uwe Kölsch iD, Nadine Unterwalder, Anna Slagman iD, Christian Meisel iD, Christine Goffinet iD, Martin Möckel iD, Horst von Bernuth iD

Clinical and Experimental Immunology · 2026

DOI: 10.1093/cei/uxaf074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2026. Verfasst von Olga Staudacher und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie …. Hauptthemen laut MEDLINE: Autoantibodies, COVID-19, Interferon Type I, SARS-CoV-2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Labor Berlin, Charité Foundation, German Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neutralizing autoantibodies against type I interferons are a risk factor for multiple severe viral diseases. The timely detection of these autoantibodies remains an unmet need. We hypothesized that paradoxically low expression of type I IFN-induced CD169/SIGLEC1 expression analyzed by flow cytometry may allow rapid screening for the presence of these autoantibodies. In a prospective cohort study, we quantified monocytic CD169/SIGLEC1 expression and neutralizing autoantibodies against type I interferons in 808 patients who presented to the emergency room with signs of acute infections during the second wave of the SARS-CoV-2 pandemic in Germany in 2021. In patients, elevated CD169/SIGLEC1 (>2400 mAb/cell) demonstrated a negative predictive value of 100% for the detection of neutralizing autoantibodies against type I interferons. Low CD169/SIGLEC1 (<2400 mAb/cell) and a CRP >50 mg/L exhibited a positive predictive value of 70% for neutralizing autoantibodies against type I interferons. We further compared the adjusted odds ratio for mortality in patients with these autoantibodies to that in patients without autoantibodies against type I interferons. Neutralizing autoantibodies against type I interferons were associated with a worse clinical outcome, independent of SARS-CoV-2 infection, implying their presence is a risk factor for a worse general outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesCOVID-19Interferon Type ISARS-CoV-2Sialic Acid Binding Ig-like Lectin 1HumansMaleFemaleMiddle AgedProspective StudiesAgedAdultAntibodies, NeutralizingGermany

Stichwörter der Autor:innen

CD169SARS-CoV-2SIGLEC1sialic acid binding Ig-like lectin 1type I interferon autoantibodies

Substanzen

AutoantibodiesInterferon Type ISialic Acid Binding Ig-like Lectin 1SIGLEC1 protein, humanAntibodies, Neutralizing

Autor:innen und Institutionen

  • Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institu…
  • Department of Immunology, Labor Berlin Charité-Vivantes, Berlin, Germany.
  • Institute of Virology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Emergency and Acute Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Department of Immunology, IMD Berlin Potsdam GbR, Berlin, Germany.
  • Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

ORCID-Profile: Olga Staudacher, Tim Meyer, Bengisu Akbil, Miriam Mayer, Uwe Kölsch, Anna Slagman, Christian Meisel, Christine Goffinet, Martin Möckel, Horst von Bernuth

Förderung

  • Labor Berlin
  • Charité Foundation
  • German Research Foundation
  • German Ministry of Education and Research
  • German Ministry of Health
  • German Innovations Funds
  • Berlin University Alliance
  • Scientific Institute of the Statutory Health Insurance Physicians

Zitieren

APA

Staudacher, O., Meyer, T., Akbil, B., Mayer, M., Schmoll, C., Kölsch, U., Unterwalder, N., Slagman, A., Meisel, C., Goffinet, C., Möckel, M., & von Bernuth, H. (2026). Autoantibodies against type I interferons correlate with low CD169/SIGLEC1 and severe non-viral infections in ER patients. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf074

Vancouver

Staudacher O, Meyer T, Akbil B, Mayer M, Schmoll C, Kölsch U, et al. Autoantibodies against type I interferons correlate with low CD169/SIGLEC1 and severe non-viral infections in ER patients. Clinical and Experimental Immunology. 2026. doi:10.1093/cei/uxaf074

BibTeX
@article{Staudacher2026,
  author = {Staudacher, Olga and Meyer, Tim and Akbil, Bengisu and Mayer, Miriam and Schmoll, Carolin and Kölsch, Uwe and Unterwalder, Nadine and Slagman, Anna and Meisel, Christian and Goffinet, Christine and Möckel, Martin and von Bernuth, Horst},
  title = {Autoantibodies against type I interferons correlate with low CD169/SIGLEC1 and severe non-viral infections in ER patients},
  journal = {Clinical and Experimental Immunology},
  year = {2026},
  doi = {10.1093/cei/uxaf074}
}
Kostenlos starten →